INS and diabetes mellitus: The majority of clinical trials evaluate moderately uncontrolled diabetes and there is limited data available describing the efficacy of these drugs in patients with poor metabolic control; however, the reduction in glucotoxicity with SGLT2 and improvement insulin sensitivity may result in an increase benefit in patients with a higher HbA1C [4, 5].